TORONTO, September 25, 2018 − 3D Signatures Inc. (TSX-V:DXD) (the “Company” or “3DS“) is pleased to announce the appointment of Dr. Sherif Louis, PhD as the Company’s Chief Executive Officer. 

Dr. Louis is an accomplished scientist and experienced leader in the biotechnology industry. Dr. Louis was an early key contributor to the development of the Company’s 3D Telomere Technology and TeloViewTM Software platform dating back almost 15 years. He has held various leadership and executive positions with Canadian non-profit orgaizations focused on advising and coaching for-profit biotech enterprises engaged in technology commercialization. Dr. Louis has also served on the Board of Directors of the Biotechnology Association of Manitoba. Dr. Louis formaly joined 3DS in September 2015 and most recently held the position of Director of Clinical Operations. 

“I am a true believer in the power of the TeloViewTM software platform. I know the science intimately and I look forward to refocusing the Company on large commercial opportunities in collaboration with strategic partners,” Sherif Louis, CEO. 

“Dr. Louis is dedicated to delivering shareholder value through prudent allocation of Company resources. 3DS will focus on opportunities that provide leverage through academic, clinical, and industry partnersnips. We are confident that Dr. Louis is the right person to lead operations during this critical transition,” Hugh Rogers, Interim Chair. 

About 3DS 

3DS (TSX-V:DXD) is a personalized medicine company with a proprietary software platform, TeloViewTM, that is designed to predict the course of certain diseases and to tailor treatment options for the individual patient. The technology is based on the three-dimensional analysis of telomeres, the protective caps at the ends of chromosomes. 3DS’ TeloViewTM software platform measures the organization of the genome and its correspondence to; the stage of a given disease, the rate of progression of the disease, how different diseases will respond to various therapies, and a drug’s efficacy and toxicity. 3DS’ proprietary imaging software is designed to go beyond identifying whether a patient suffers from a specific disease or condition. Instead, the TeloViewTM platform is designed to inform clinicians and patients with respect to how to personalize treatment and best manage an individual’s disease based on their unique TeloViewScoreTM. As healthcare moves increasingly toward better informed, patient-centric approaches, the Company intends for the TeloViewTM platform to deliver personalized medicine that allows for better treatments, leading to better outcomes. 

The TeloViewTM platform is supported by 25 clinical studies involving more than 3,000 patients and 20 different cancers, plus Alzheimer’s disease. 3DS benefits from twenty years of research, $25M of non-dilutive investment into its platform and more than 130 supporting publications, and holds a portfolio of patents related to three-dimensional telomere analysis for proliferative diseases, including (but not limited to) hematological disorders such as Hodgkin’s lymphoma, multiple myeloma, and chronic myeloid leukemia. 3DS’ intellectual property portfolio also covers prostate cancer, breast cancer, lung cancer, melanoma, colorectal cancer, and Alzheimer disease. 

For more information, visit the Company’s website at: http://www.3dsignatures.com. 

For further information, please contact: 

Hugh Rogers 

Interim Chair 

416-673-8487 

MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto ON, M5G 1L7 www.3dsignatures.com TSX.V: DXD 

info@3dsignatures.com 

MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto ON, M5G 1L7 

www.3dsignatures.com 

TSX.V: DXD 

TSX Venture Exchange Disclaimer 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

Cautionary Note Regarding Forward-Looking Statements 

Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “intends”, “will”, or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding access to funding, commercial opportunities, the Company’s assessment of current clinical programs, and efficacy and success of the TeloViewTM platform are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.